Article in the highly subscribed EurActiv journal

Commission urged to consider common regulatory framework for nanomedicines” supports the EAASM goals for nanomedicines and nanosimilars for regulatory clarity

The lack of a fit-for-purpose regulatory framework on nanomedicines and their “generics” poses risks for the safety of EU patients and the European Commission should urgently look to address this, the Director of the European Alliance for Access to Safer Medicines (EAASM) stated.

To read the article, click here.